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INTRODUCTION
Clusterin is a disulphide-linked heterodimeric protein that 
plays an anti-apoptotic role in the cells.1 Clusterin plays the role 
of a chaperone, which enables proteins to be secreted by fold-
ing their structure. Through this mechanism, clusterin facili-
tates the activity of pro-apoptotic and anti-apoptotic entities.1 
Additionally, clusterin has been reported to play anti-inflam-
matory roles by downregulating the transcriptional activity of 
nuclear factor-kappa B (NF-κB) in several systemic autoim-
mune diseases, such as rheumatoid arthritis and systemic lupus 
erythematosus.2 Moreover, the concentration of clusterin was 
reported to be low in both active rheumatoid arthritis and sys-
temic lupus erythematosus due to the regulation of and loss of 
ability to inactivate lupus-specific complements, respectively.3,4
Antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) comprises vasculitis of two small vessels to-
gether with immune complex small-vessel vasculitis. AAV is 
characterised by necrotising vasculitis in capillaries and adja-
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cent arterioles and venules and has three subtypes: microscop-
ic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), 
and eosinophilic GPA (EGPA).5,6 Given that the role of NF-κB 
in the pathogenesis of AAV is well known,7,8 it can be reason-
ably speculated that the serum level of clusterin might be in-
versely correlated with the current disease activity of AAV.
A previous study investigated new biomarkers of disease ac-
tivity among serum proteins in AAV. The previous study, how-
ever, could provide no clinical significance of clusterin levels 
in the comparison analysis between patients with AAV and 
healthy controls.9 Nevertheless, given the lack of information 
on the relationship between serum clusterin level and the cur-
rent AAV-specific indices in the previous study, we believe that 
it may be valuable to reassess the clinical implication of serum 
clusterin levels in patients with AAV. Hence, in this study, we 
randomly selected patients from a cohort of patients with AAV 
in a single centre and investigated whether serum clusterin 
levels could reflect the current AAV-specific indices.
MATERIALS AND METHODS
Patients 
We randomly selected 57 patients with AAV from the Sever-
ance Hospital ANCA-associated VasculitidEs (SHAVE) cohort, 
which is a prospective and observational cohort including pa-
tients with MPA, GPA, and EGPA that was established in No-
vember 2016. The diagnosis of AAV in all patients was confirmed 
at the Division of Rheumatology, Department of Internal Med-
icine, Yonsei University College of Medicine, and Severance 
Hospital. All AAV patients in the SHAVE cohort met both the 
2007 European Medicines Agency algorithms for AAV and 
polyarteritis nodosa and the 2012 revised International Cha-
pel Hill Consensus Conference Nomenclature of Vasculitides 
criteria.5,6 This study was approved by the Institutional Review 
Board (IRB) of Severance Hospital (4-2016-0901) and, when 
required, the written informed consent was obtained from 
patients at the time of blood sampling. The IRB waived the 
need for written informed consent if it had been previously 
obtained while entering the SHAVE cohort.
Clinical and laboratory data
Age and sex were included as demographic data. The AAV sub-
types and ANCA types were reviewed. Clinical manifestations 
were assessed based on nine clinical categories, and subitems 
of the Birmingham vasculitis activity score (BVAS) were inves-
tigated. Acute phase reactants, erythrocyte sedimentation rate 
(ESR), and C-reactive protein (CRP) levels were also measured. 
The disease duration was defined as the period from the time 
of AAV diagnosis to the time of blood sampling.
AAV-specific indices 
In terms of AAV-specific indices, we included the Korean ver-
sion of the Short-Form 36-Item Health Survey Physical and 
Mental Component Summaries (SF-36 PCS and SF-36 MCS) 
scores,10 BVAS version 3,11 five-factor score (FFS),12 and vascu-
litis damage index (VDI).13
Blood collection and storage
Whole blood was collected after obtaining patient consent 
and sera were isolated and stored at -80°C. All AAV-specific in-
dices were assessed, and tests for acute phase reactants were 
performed on the day of blood collection. 
High disease activity 
In this study, the highest tertile of BVAS (≥16) was defined as 
high activity of AAV.
Measurement of serum clusterin levels
Serum clusterin levels were measured in stored sera using en-
zyme-linked immunosorbent assay kits (R&D Systems, Minne-
apolis, MN, USA) according to the manufacturer’s instructions. 
Healthy controls 
To compare serum clusterin levels between patients with AAV 
and healthy controls, serum samples were obtained from 40 
healthy controls who underwent regular check-ups at the 
healthcare centre of Severance Hospital. The use of clinical 
data from healthy controls was approved by the IRB of Sever-
ance Hospital (4-2017-0761).
Statistical analyses 
All statistical analyses were performed using IBM SPSS Statis-
tics for Windows, version 25 (IBM Corp., Armonk, NY, USA). 
Continuous variables are expressed as medians with inter-
quartile ranges, whereas categorical variables are expressed 
as numbers (percentages). The correlation coefficient (r) be-
tween the two variables was obtained using the Pearson’s cor-
relation analysis. Significant differences between two continu-
ous variables and among the three continuous variables were 
compared using the Mann-Whitney U test and analysis of vari-
ance test, respectively. The standardised correlation coefficient 
(β) was obtained by multivariable linear regression analysis 
using variables with statistical significance in the univariable 
analysis. The optimal cut-off was extrapolated by performing 
receiver operator characteristic (ROC) curve analysis, and one 
value with the maximum sum of sensitivity and specificity was 
selected. The relative risk (RR) of the cut-off for the high activ-
ity of AAV was analysed using contingency tables and the chi-
square test. Statistical significance was set at p<0.05.
RESULTS
Characteristics 
At the time of blood collection, the median age of patients with 
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AAV was 64.0 years and 19 patients were males. Twenty-nine 
patients had MPA, 17 had GPA, and 11 had EGPA. The median 
serum clusterin level was 168.2 μg/mL. AAV-specific indices, 
as well as clinical and laboratory data are presented in Table 1. 
Until blood collection, glucocorticoids, azathioprine, cyclo-
phosphamide, and rituximab were administered to 75.9%, 
29.3%, 8.6%, and 5.2% of patients with AAV, respectively.
Correlations 
Among AAV-specific indices and acute phase reactants, SF-36 
PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r= 
-0.404), ESR (r=-0.336), and CRP levels (r=-0.421) were signifi-
cantly correlated with serum clusterin levels (Table 2). 
Linear regression for BVAS 
Among AAV-specific indices and serum clusterin levels, in the 
univariable linear regression analysis, SF-36 PCS score, SF-36 
MCS score, FFS, and serum clusterin were significantly corre-
lated with BVAS. In the multivariable analysis, both FFS [β= 
0.412; 95% confidence interval (CI) 1.258, 4.910] and serum 
clusterin level (β=-0.250; 95% CI -0.056, -0.001) were signifi-
cantly associated with BVAS in patients with AAV (Table 3).
Comparison of serum clusterin levels between 
patients with AAV and BVAS≥16 and those with 
BVAS<16
Serum clusterin levels were compared between patients with 
AAV and BVAS<16 and those with BVAS≥16. Patients with high 
AAV activity exhibited significantly lower serum clusterin lev-
els than did those with low AAV activity (159.3 μg/mL vs. 185.0 
μg/mL, p=0.017) (Fig. 1A). However, there was no significant 
difference in serum clusterin levels among AAV subtypes.
Comparison of serum clusterin levels among three 
AAV subtypes 
The median serum clusterin levels were 167.9 μg/mL, 191.1 
μg/mL, and 165.7 μg/mL in MPA, GPA, and EGPA patients, re-
spectively. There were no significant differences among the 
three groups (Supplementary Fig. 1, only online).
Comparison of serum clusterin levels based on organ 
involvement
Patients with AAV who had general manifestations exhibited 
a significantly lower serum clusterin level than did those with-
out general manifestations (162.0 μg/mL vs. 185.3 μg/mL; p= 
0.031). Additionally, patients with AAV who had pulmonary 
manifestations showed a significantly lower serum clusterin 
level than did those without pulmonary manifestations (164.6 
μg/mL vs. 205.1 μg/mL; p=0.038) (Supplementary Table 1, only 
online).
Optimal cut-off of serum clusterin level
Using the ROC curve (area 0.704; 95% CI 0.559, 0.849; p=0.017), 
Table 1. Characteristics of 57 Patients with AAV
Variables at the time of blood collection Values 
Demographic data 
Age (yr) 64.0 (21.0)






MPO-ANCA (or P-ANCA) positivity 33 (57.9)
PR3-ANCA (or C-ANCA) positivity 6 (10.5)
Both ANCAs 1 (1.8)
ANCA negativity 14 (24.6)
No results 5 (8.8)
AAV-specific indices 
SF-36 PCS 50.9 (36.6)











Gastrointestinal  2 (3.5)
Renal 32 (56.1)
Nervous 18 (31.6)
Acute phase reactants 
ESR (mm/hr) 29.0 (67.0)
CRP (mg/L) 3.0 (36.7)
Serum clusterin (μg/mL) 168.2 (65.7)
Until blood collection 






Mycophenolate mofetil 0 (0)
Tacrolimus 0 (0)
Methotrexate 1 (1.7)
AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; 
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, 
eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; P, peri-
nuclear; PR3, proteinase 3; C, cytoplasmic; SF-36, short-form 36-item; PCS, physi-
cal component summary; MCS, mental component summary; BVAS, Birming-
ham vasculitis activity score; FFS, five-factor score; VDI, vasculitis damage index; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Values are expressed as median [interquartile range] or n (%).
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130.45 μg/mL was identified as the optimal serum clusterin 
cut-off level for high activity of AAV (sensitivity 90.2% and spec-
ificity 43.7%) (Fig. 1B). 
Relative risk 
When we divided the patients with AAV into two groups based 
on the cut-off of serum clusterin level, 16 of 57 patients with AAV 
were included in the group with serum clusterin level ≤130.45 
μg/mL. High AAV activity was identified more frequently in 
patients with serum clusterin level ≤130.45 μg/mL than in those 
with serum clusterin level >130.45 μg/mL (43.8% vs. 9.8%; p= 
0.003). Furthermore, patients with serum clusterin level ≤130.45 
μg/mL had a significantly higher risk for high activity of AAV 
than did those with serum clusterin level >130.45 μg/mL (RR 
7.194; 95% CI 1.725, 30.010) (Fig. 1C).
Comparing serum clusterin levels between patients 
with AAV and healthy controls
Patients with AAV exhibited significantly lower serum cluster-
in levels than did healthy controls (168.2 μg/mL vs. 230.5 μg/mL; 
p<0.001) (Fig. 2).
DISCUSSION
In this study, we investigated whether serum clusterin level 
could reflect the current AAV-specific indices in patients with 
AAV and obtained several important findings: 1) serum clus-
terin level was significantly correlated with SF-36 PCS score, 
SF-36 MCS score, and BVAS among AAV indices; 2) patients 
with AAV who had the highest tertile of BVAS exhibited a low-
er serum clusterin than did those without the highest tertile of 
BVAS; 3) patients with AAV who had serum clusterin levels 
≤130.45 μg/mL had a significantly higher risk for high activity 
of AAV than did those with serum clusterin levels >130.45 μg/
mL (RR 7.194); 4) patients with AAV exhibited a significantly 
Fig. 1. Cut-off of serum clusterin level for high AAV activity. (A) Patients with high AAV activity exhibited significantly lower serum clusterin levels than did 
those with low AAV activity. (B) The optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 μg/mL (sensitivity 90.2% and 
specificity 43.7%). (C) Patients with serum clusterin level ≤130.45 μg/mL had a significantly higher risk for high activity of AAV than did those with serum 
clusterin level >130.45 μg/mL (RR 7.194). AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis activity 
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Table 2. Correlation between Serum Clusterin and Continuous Variables 
at Blood Collection in AAV Patients
Variables at the time 





Age (yr) 0.037 0.787
AAV-specific indices 
SF-36 PCS 0.328 0.013




Acute phase reactants 
ESR (mm/hr) -0.336 0.013
CRP (mg/L) -0.421 0.001
AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; 
SF-36, short-form 36-item; PCS, physical component summary; MCS, mental 
component summary; BVAS, Birmingham vasculitis activity score; FFS, five-fac-
tor score; VDI, vasculitis damage index; ESR, erythrocyte sedimentation rate; 
CRP, C-reactive protein.
Table 3. Linear Regression Analysis of AAV-Specific Indices and Serum Clusterin for the Current BVAS in Patients with AAV
Variables
Univariable Multivariable
Beta 95% CI p value Beta 95% CI p value
SF-36 PCS -0.375 -0.183, -0.037 0.004 -0.133 -0.143, 0.065 0.454
SF-36 MCS -0.306 -0.189, -0.017 0.019 -0.077 -0.138, 0.087 0.648
FFS 0.490 1.916, 5.408 <0.001 0.412 1.258, 4.910 0.001
VDI 0.144 -0.492, 1.661 0.282 0.003 -0.962, 0.989 0.978
Clusterin -0.343 0.000, 0.000 0.008 -0.250 -0.056, -0.001 0.043
ANCA, antineutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; BVAS, Birmingham vasculitis activity score; SF-36, short-form 36-item; PCS, physi-
cal component summary; MCS, mental component summary; FFS, five-factor score; VDI, vasculitis damage index; CI, confidence interval.
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lower serum clusterin level than did healthy controls. Based on 
these results, we concluded that serum clusterin level could 
reflect the current SF-36 score and BVAS and serum clusterin 
level below the optimal cut-off might indicate high activity of 
AAV.
We contemplated how serum clusterin levels reflect the cur-
rent BVAS in patients with AAV (Table 3 and Fig. 1C) and why it 
was lower in patients with AAV compared to healthy controls 
(Fig. 2). Although the function of secreted clusterin is not fully 
understood, it is known that secreted clusterin has an anti-
apoptotic role in the regulation of cell proliferation and extra-
cellular tissue remodelling.14 We drew the following three hy-
potheses for low serum clusterin levels in patients with AAV 
and their reflection to BVAS. The first hypothesis is that intra-
cellular signal transduction is inhibited during inflammation. 
Clusterin may stabilise IκB, which in turn reduces transcrip-
tion of the NF-κB genes, increasing in the anti-inflammatory 
process.15
On the other hand, in the introduction section, we described 
that clusterin has been reported to play anti-inflammatory roles 
by downregulating the transcriptional activity of NF-κB in sev-
eral autoinflammatory diseases. However, due to the limita-
tion of the one-time cross-sectional study being designed as a 
pilot study, we could not additionally measure the serum con-
centration of the biomarker that can directly reflect the expres-
sion level of the NF-κB downstream gene. Meanwhile, a previ-
ous study reported that the over-expression of NF-κB could the 
production of endogenous CRP.16 Based on these results, it may 
be inferred that serum CRP could indirectly reflect the degree 
of activation of NF-κB. In summary, it can be hypothesized that 
clusterin may reduce the transcriptional activity of NF-κB, 
which leads to a decrease in the production of endogenous 
CRP. The result that serum clusterin showed a significant in-
verse correlation with serum CRP (r=-0.336, p=0.013) may sup-
port this hypothesis (Table 2).
The second hypothesis was based on the repolarisation of 
macrophages. Clusterin may repolarise M1 macrophages (pro-
inflammatory) to M2 macrophages (anti-inflammatory). There-
fore, low serum clusterin level may lead to inflammatory mi-
croenvironments with diminished phagocytic activity, and 
thereby reducing the clearance of dead cells.17 The last hypoth-
esis was based on the interaction between clusterin and the 
complement pathway. A low level of clusterin activates the 
complement pathway, and therefore, more C5b is required by 
splitting C5.18 This status leads to an increase in C5a, which 
could form a vicious circle of accelerating the inflammatory 
process in the pathogenesis of AAV.19
Additionally, we contemplated how serum clusterin level 
was significantly correlated with the current SF-36 PCS and SF-
36 MCS scores. In this study, serum clusterin levels were sig-
nificantly correlated with BVAS, SF-36 PCS score, and SF-36 
MCS score (Table 2). Additionally, BVAS was significantly cor-
related with both SF-36 PCS and SF-36 MCS scores (Table 3). 
That is, a triangular correlation was formed among serum clus-
terin, BVAS, as well as SF-36 PCS and SF-36 MCS scores. To elu-
cidate the relationship between serum clusterin level, BVAS, 
and SF-36 scores, we conducted univariable and multivariable 
linear regression analyses with AAV-specific indices and serum 
clusterin level for the current SF-36 PCS score.
In the univariable analysis, BVAS (r=-0.374) and serum clus-
terin level (r=0.328) were significantly correlated with SF-36 
PCS score. FFS tended to be correlated with serum clusterin 
level; however, it did not reach statistical significance (p=0.063). 
Given its p-value and clinical significance, we performed the 
multivariable analysis twice. In the multivariable analysis with-
out FFS, only BVAS (β=-0.289, 95% CI -1.914, -0.061) was signifi-
cantly associated with SF-36 PCS score. However, in another 
multivariable analysis with FFS, none of the variables were as-
sociated with SF-36 PCS score (Supplementary Table 2, only 
online). Based on these results, we concluded that unlike the 
direct correlation between serum clusterin level and BVAS, se-
rum clusterin level is thought to have an indirect relationship 
with SF-36 PCS score.
A previous study known as the “the Rituximab in ANCA-As-
sociated Vasculitis (RAVE)” trial, compared the serum levels of 
28 proteins in patients with AAV with an active status, those in 
remission, and healthy controls, and found no difference in se-
rum clusterin levels between them.9 However, our cross-sec-
tional observational study revealed that serum clusterin levels 
in patients with AAV were significantly lower than those in 
healthy controls. We attribute this discrepancy to ethnic and 
geographical differences; only one Asian patient with AAV was 
included in the RAVE study.20 Therefore, we think that the dis-
crepancy between the results of the RAVE study and our study 
does not necessarily mean that our study is less convincing. 
Rather, considering the racial and geographic situation in which 
Korean AAV patients need to be treated, we view this discrep-
ancy as valuable information that provides insight to a new 
phenomenon.

















AAV patients Healthy controls
p<0.001
Fig. 2. Comparison of serum clusterin levels between AAV patients and 
healthy controls. Patients with AAV exhibited significantly lower serum 
clusterin levels than did healthy controls. AAV, ANCA-associated vasculi-
tis; ANCA, antineutrophil cytoplasmic antibody.
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compared to MPA and GPA. For this reason,21 large-scale clin-
ical studies are sometimes conducted with only MPA and GPA 
patients.9,20,22 Therefore, we included only 29 MPA patients and 
17 GPA patients and analysed them again. In the correlation 
analysis, serum clusterin was significantly correlated with BVAS 
(r=-0.399, p=0.006), ESR (r=-0.384, p=0.010), and CRP (r=-0.478, 
p=0.001). In the ROC curve of serum clusterin for BVAS ≥16 
(area 0.723; 95% CI 0.572, 0.874; p=0.014), 130.45 μg/mL was 
also identified as the optimal serum clusterin cut-off level for 
high activity of MPA and GPA (sensitivity 93.3% and specifici-
ty 43.7%). MPA and GPA patients with serum clusterin level 
≤130.45 μg/mL had a significantly higher risk for high activi-
ty of MPA and GPA than did those with serum clusterin level 
>130.45 μg/mL (RR 10.889; 95% CI 1.908, 62.144). This result 
implies that the RR of the cut-off of serum clusterin in patients 
with MPA and GPA was statistically more convincing than that 
in patients with all subtypes of AAV. Lastly, we compared se-
rum clusterin levels between MPA and GPA patients and healthy 
controls. Similar to the comparison analysis between AAV pa-
tients and healthy controls, MPA and GPA patients exhibited 
significantly lower serum clusterin levels compared to healthy 
controls (168.2 μg/mL vs. 230.5 μg/mL; p=0.003). 
Overall, the results of this additional analysis were not differ-
ent from those in all AAV patients. In addition, the discovery of 
biomarkers for AAV patients, not limited to MPA and GPA, has 
two clinical advantages. One is that it can be applied clinically 
even if the subtype has not yet been finalized in the course of 
AAV diagnosis. The other is that, albeit rare, there may be a case 
of alteration of the AAV subtype during follow-up. Even in this 
case, it can be continuously applied to clinical trials. For this 
reason, we believe the results of our study, which included all 
AAV patients, are convincing enough, compared to those in-
cluding only patients with MPA and GPA.
Among the nine clinical items of BVAS, general manifesta-
tions and pulmonary manifestations were associated with low 
levels of serum clusterin in the same pattern of correlation as 
BVAS. In addition, when the correlation between the sum of 
each clinical item and serum clusterin level was investigated, 
the sum of general manifestations (r=-0.333, p=0.011) and pul-
monary manifestations (r=-0.262, p=0.049) showed significant 
inverse correlations with serum clusterin level. Therefore, al-
though it is challenging to elucidate the exact mechanism, it 
can be predicted that general manifestations and pulmonary 
manifestations contribute to the inverse correlation between 
BVAS and serum clusterin level.
The immunological roles of the NK-κB signalling and the 
complement pathway in the pathogenesis of renal involve-
ment of AAV are well established. Therefore, according to the 
hypothesis of an anti-inflammatory action to reduce NF-κB 
signalling by stabilizing IκB, serum clusterin levels in AAV pa-
tients with renal involvement should have been lower than 
those without renal involvement; however, there was no sig-
nificant difference between the two groups. Here, we raise two 
questions. First, would the results be different if only MGA and 
GPA patients were included? Similar to the results of the anal-
ysis including all subtypes of AAV patients, serum clusterin 
levels in MPA and GPA patients with renal involvement were 
higher than those without renal involvement, but it did not 
reach statistical significance (184.8 μg/mL vs. 163.1 μg/mL, p= 
0.319). Second, should NF-κB signalling, which determines se-
rum clusterin levels, only be associated with renal involvement? 
The mechanisms of NF-κB signalling and renal injury are well 
established.8 On the other hand, like kidney injury through NF-
κB, NF-κB signalling is known to play an important role in lung 
injury.23 In this study, the frequency of pulmonary involvement 
was higher than that of renal involvement (71.9% vs. 56.1%). 
This difference may be the reason for the discrepancy between 
the expected association between renal invasion and serum 
clusterin levels by NF-κB signalling and the results of this study.
The primary limitations of the current study are its cross-sec-
tional design and the small number of patients included in the 
study. In this study, the longitudinal and serial measurement 
of serum clusterin was not performed. We believe that a future 
prospective study that measures serum clusterin levels using 
paired samples before and after treatments and includes a larg-
er number of patients with AAV will provide more valuable 
clinical information on the implications of serum clusterin 
levels for patients with AAV.
In conclusion, serum clusterin levels were detected at a low-
er concentration in the sera of patients with AAV than in those 
of healthy controls and could reflect the current disease activ-
ity in patients with AAV. We believe that serum clusterin level 
will be a useful biomarker for assessing the current activity of 
AAV and expect that it will help elucidate the pathophysiology 
of AAV.
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